PMGC secures 5% Elevai Skincare royalty via payment agreement with Longevity Health

PMGC Holdings Inc.

Agreement with Longevity Health (formerly Carmell) converts 5% net sales royalty from Jan 2025 Elevai Skincare sale into monthly payments.
2025 royalty acknowledged at $94,937 with interest at WSJ Prime +1% from April 2026 due date until paid.
Monthly installments of $10,000 begin Oct 15, 2026; all amounts due by Aug 28, 2031.
Mandatory prepayments of 15% of net proceeds from capital raises >$350k, asset sales, settlements; annual audit rights.
Payments are non-dilutive to shareholders; future royalty and earnout payments are added to the plan on interest-bearing terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.